NCT00897091View on ClinicalTrials.gov

S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil

CompletedOBSERVATIONAL

Enrollment

750

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Breast Cancer

Interventions

GENETIC

comparative genomic hybridization

GENETIC

microarray analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

diagnostic laboratory biomarker analysis

Trial Locations (1)

60153

Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

SWOG Cancer Research Network

NETWORK

NCT00897091 - S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil | Biotech Hunter | Biotech Hunter